share_log

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13

HC Wainwright & Co.維持對加的夫腫瘤學的買入,將目標股價下調至13美元
Benzinga ·  2023/08/08 07:23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $14 to $13.

HC Wainwright & Co. 分析師Raghuram Selvaraju維持加的夫腫瘤學(納斯達克股票代碼:CRDF)的買入,並將目標股價從14美元下調至13美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論